427 results about "Elevated creatinine" patented technology

The invention discloses a xanthine oxidase inhibitory peptide with a kidney improving function and application thereof, and belongs to the technical field of biological medicines.The xanthine oxidase inhibitory peptide is screened out by conducting enzymolysis, separation and purification on litopenaeus vannamei processing by-products and utilizing a molecular docking technology, the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Leu-Gly-Pro-Pro-Pro, and the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Leu-Gly-Pro-Pro-Pro. And the half inhibition concentration of the polypeptide is 2.356 + / -0.2448 mM. The xanthine oxidase inhibitory peptide is proved to have an improvement effect on hyperuricemia mice, the improvement effect is mainly characterized by reducing the content of serum uric acid, creatinine and urea nitrogen of the hyperuricemia mice, inhibiting the activity of xanthine oxidase (XOD) in serum and livers of the mice, inhibiting synthesis of uric acid and improving kidney injury of the mice, and Toxinpred prediction shows that the xanthine oxidase inhibitory peptide has the effect of inhibiting the activity of xanthine oxidase (XOD) in the serum and livers of the mice. The xanthine oxidase inhibitory peptide is free of toxic and side effects, so that the xanthine oxidase inhibitory peptide has a wide application prospect in preparation of food or drugs for improving renal functions.

The invention discloses a xanthine oxidase inhibitory peptide with uric acid reducing activity and application thereof, and belongs to the technical field of biological medicines.The xanthine oxidase inhibitory peptide is obtained by conducting enzymolysis, separation and purification on processing byproducts such as litopenaeus vannamei heads and shells with xanthine oxidase inhibitory activity. The xanthine oxidase inhibitory peptide is screened by using a molecular docking technology, and the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Pro-Val-Pro-Pro-Pro. The xanthine oxidase inhibitory peptide has an XOD (X-Oxidase) half inhibitory concentration of 3.181 + / -0.1786 mM. The invention further proves that the xanthine oxidase inhibitory peptide has a certain improvement effect on hyperuricemia mice, and the xanthine oxidase inhibitory peptide mainly has the effects of reducing the content of serum uric acid, creatinine and urea nitrogen of the hyperuricemia mice, inhibiting the activity of xanthine oxidase (XOD) in serum and liver of the mice, inhibiting synthesis of uric acid and improving kidney injury of the mice, and the xanthine oxidase inhibitory peptide has a certain improvement effect on the hyperuricemia mice through Toxinpred prediction. The xanthine oxidase inhibitory peptide uric acid reducing peptide is free of toxic and side effects and has a wide market application prospect.

Computer-implemented methods of predicting the QTc of a subject in response to administration of QTc prolonging drugs, especially those that are dose adjusted for renal function, such as antiarrhythmic drugs. Included is a method of administering an antiarrhythmic drug to a subject, comprising: providing as inputs into a treatment management application i) Baseline QTc and ii) at least a Creatinine Clearance, Weight, Age, Sex, or Heart Rate; the treatment management application providing as an output one or more predicted QTc or predicted QTc range for the subject expected from administration of a 1-5 hour IV dose, alone or followed by one or more oral doses, of an antiarrhythmic drug to the subject; and upon the one or more QTc or QTc range being within an acceptable range, administering the 1-5 hour IV dose to the subject optionally followed by administering one or more of the oral doses to the subject.

Methods of administering sotalol hydrochloride in an amount effective for treating one or more cardiovascular disease or disorder in pediatric patients are described and include IV and / or oral doses based on age-specific creatinine clearance ranges.

The invention discloses application of an RNF130 activator in preparation of a medicine for preventing and / or treating acute kidney injury, and belongs to the technical field of biological medicine. The invention provides an application of an RNF130 activator in preparation of a medicine for preventing or treating renal ischemia-reperfusion injury, the RNF130 activator can improve the renal function of a mouse suffering from renal ischemia-reperfusion injury, improve the levels of serum creatinine, urea nitrogen and cystatin C, reduce the levels of kidney injury markers KIM-1 and LCN2, reduce renal tubule injury, improve the renal function of the mouse suffering from renal ischemia-reperfusion injury, improve the renal function of the mouse suffering from renal ischemia-reperfusion injury and improve the renal function of the mouse suffering from renal ischemia-reperfusion injury and the renal function of the mouse suffering from renal ischemia-reperfusion injury. Therefore, the compound plays a role in preventing and treating the kidney ischemia reperfusion injury, and a new target is provided for preparing the medicine for preventing and treating the acute kidney injury.

The invention belongs to the technical field of medicines, and particularly relates to application of eupatorium chinense extract in preparation of a medicine for treating gout. Researches show that the eupatorium chinense extract and the active components thereof have good biological activity and can inhibit the activity of xanthine oxidase (XOD). Molecular docking experiments also show that the eupatorium chinense extract and xanthine oxidase have good binding energy. Further research finds that the eupatorium chinense extract can reduce the levels of uric acid and creatinine in serum in a hyperuricemia mouse body, and has good uric acid reducing activity. In the field of treatment of hyperuricemia and gout, many traditional medicines have many adverse reactions. Compared with the prior art, the eupatorium chinense serving as a traditional Chinese medicine provides a safe and effective natural medicine for treating hyperuricemia and gout or gout complications due to the efficient uric acid reducing effect of the eupatorium chinense.

The invention discloses an intestinal strain capable of effectively regulating uric acid metabolism, a microbial agent of the intestinal strain and application of the intestinal strain in uric acid reducing products, and belongs to the technical field of microorganisms. According to the enterococcus pluvialis ZQ205, the enterococcus pluvialis ZQ205 which is free of toxic and side effects and capable of effectively relieving and treating the hyperuricemia is found for the first time, and the collection number of the enterococcus pluvialis ZQ205 in the China Center for Type Culture Collection is CCTCC NO: M 2025844; the strain can significantly reduce the levels of uric acid, creatinine and urea nitrogen in serum of mice, can effectively reduce the levels of inflammatory factors such as IL-6 and TNF-alpha in serum of hyperuricemia mice, and can improve kidney injury caused by hyperuricemia.

The invention discloses a fungus extract capable of effectively regulating uric acid metabolism and relieving inflammation as well as a preparation method and application of the fungus extract, and belongs to the technical field of deep processing of edible fungi. Schizophyllumcommuneh and poplar phellinus sporocarp are mixed and extracted, and the prepared fungus extract can effectively inhibit activity of xanthine oxidase in serum and liver of mice, reduce content of uric acid, creatinine, urea nitrogen and the like in serum and promote excretion of uric acid, creatinine, urea nitrogen and the like in urine; meanwhile, the content of inflammatory markers such as IL-6 and TNF-alpha in mouse serum can be effectively reduced, inflammatory infiltration of liver and kidney cells is relieved, and the problem that an existing edible mushroom extract is not ideal in treatment effect on hyperuricemia is solved.

The invention discloses a traditional Chinese medicine composition with the effects of benefiting qi, nourishing blood, invigorating the spleen and tonifying the kidney and a preparation method of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: cistanche, ginseng, American ginseng, astragalus membranaceus, medlar, rhizoma polygonati, oyster peptide, angelica sinensis, radix rehmanniae preparata, donkey-hide gelatin, fructus amomi, pericarpium citri reticulatae, hawthorn, folium cortex eucommiae, radix puerariae, liquorice and the like. The preparation method comprises the following steps: respectively crushing the medicinal materials, dissolving the colla corii asini, mixing, adding water, granulating and the like. The composition can be prepared into various dosage forms such as granules, capsules, tablets, oral liquid and the like. Experiments show that the traditional Chinese medicine composition can effectively improve the symptoms of deficiency of qi and blood (increasing erythrocyte count and hemoglobin content), weakness of spleen and stomach (increasing body weight and improving pepsin activity) and kidney deficiency (reducing creatinine and urea nitrogen content and improving SOD activity), and acute toxicity experiments show that the toxicity is slightly reversible under high dosage, and the safety is good under therapeutic dosage. The traditional Chinese medicine composition has potential application value in the aspect of preparing medicines for benefiting qi, nourishing blood, invigorating spleen and tonifying kidney.

The invention relates to the technical field of medical data analysis, in particular to a kidney injury prediction system based on big data, which comprises a physiological data processing module, a fluctuation analysis construction module, a dynamic weight evaluation module, a cross-domain data scheduling module and a risk trend prediction module. According to the method, through timestamp standardization and continuous recombination of the acute kidney injury physiological data, the consistency of multi-source monitoring data in the time dimension is ensured, drifting and dislocation are eliminated, the time sequence integrity is improved, fluctuation points of serum creatinine and urine volume are extracted, sensitive time slices are recognized, and high-risk time point early warning is achieved; a rate change comparison mechanism is introduced, a physiological factor weight sequence is generated, factor influence evaluation is enhanced, uploading frequency and a time delay state are combined, high-reliability nodes are screened, data continuity and real-time performance are improved, index trend deviation is tracked, a mode label is generated, and timeliness and accuracy of renal function change prediction are improved.

The invention belongs to the technical field of disease risk assessment, and discloses a hearing loss disease risk prediction method, system and device and a medium, and the method comprises the steps: obtaining hearing test data, serum creatinine detection data and genetic typing data of a tester; calculating estimated glomerular filtration rate data based on the serum creatinine detection data; screening SNP (Single Nucleotide Polymorphism) sites related to hearing loss in the genetic typing data, and calculating multi-gene risk scoring data on the basis of the SNP sites; based on a statistical method, combining the hearing test data, the estimated glomerular filtration rate data, the polygene risk scoring data and the basic feature data of the test personnel to construct a hearing loss disease risk prediction model; and predicting the hearing loss of the person to be predicted and the illness risk probability of the severity of the hearing loss based on the constructed hearing loss illness risk prediction model. According to the technical scheme, genetic and non-genetic factors are comprehensively considered, and the hearing loss disease risk can be evaluated more comprehensively and accurately.

The invention belongs to the technical field of microorganisms, and particularly relates to application of Ackerman muciniphila in preparation of diabetic metabolic disease related renal injury products. The preservation number of the ackermann muciniphile is CGMCC (China General Microbiological Culture Collection Center) No.20955. The ackermann muciniphile provided by the invention can be used for remarkably reducing the indexes of blood urea nitrogen, serum creatinine and urine protein and improving the renal function; the oxidative stress of the kidney is relieved by reducing the malondialdehyde level and improving the activity of SOD, CAT and GSH-Px; the TLR4 / NF-kappa B pathway is inhibited, TNF-alpha and IL-1beta secretion is reduced, and inflammatory response is relieved; finally, the kidney protection effect is achieved through the anti-oxidation, anti-inflammatory and anti-fibrosis effects.

The invention belongs to the field of biological medicines, and particularly discloses application of a Ptprj agonist GJ103 in preparation of a medicine for treating acute kidney injury (AKI) induced by cisplatin. In-vivo and in-vitro experiments prove that the GJ103, by activating Ptprj, can significantly down-regulate expression of pro-apoptotic protein Bax and Cleved Caspase-3, up-regulate anti-apoptotic protein Bcl2 and reduce infiltration of inflammatory factors TNF-alpha and IL-6, so that apoptosis and inflammatory response of renal tubular epithelial cells are relieved. In in-vivo experiments, GJ103 (20-40mg / kg / day) can reduce serum creatinine and urea nitrogen levels of cis-platinum model mice and improve pathological injuries such as renal tubule dilatation; in in-vitro experiments, 20-40 [mu] M of GJ103 can inhibit apoptosis of renal tubular epithelial cells and reduce expression of renal injury markers NGAL and Kim-1. The pharmaceutical composition contains GJ103 and a pharmaceutical carrier, the preparation form can be a 4mg / mL injection (the purity is greater than or equal to 99.46%) or an oral preparation, and a new strategy is provided for clinical treatment of cisplatin renal toxicity.

The invention discloses application of oligopeptide in preparation of a medicine for treating and / or preventing diabetic nephropathy. The oligopeptides comprise oligopeptides with the amino acid sequence of SEQ ID NO: 1: LNLYP and derivative sequences or conservative substitution variants of the oligopeptides. The oligopeptide can significantly improve renal function indexes of mice with diabetic nephropathy, such as UACR, serum creatinine, urea nitrogen and the like, enhance podocyte barrier integrity and inhibit accumulation of advanced glycosylation end products AGEs in kidney tissues, and provides a basis for development of novel drugs for treating diabetic nephropathy.

The invention belongs to the technical field of biological medicines, and particularly relates to a morinda officinalis-synanthrin composition and application thereof in renal fibrosis products. The radix morindae officinalis-synanthrin composition provided by the invention is prepared from radix morindae officinalis polysaccharide, synanthrin and water, the synergistic effect of the two polysaccharides can be exerted, the physical and chemical properties and biological activity of the radix morindae officinalis-synanthrin composition can be improved, the metabolic rate of the kidney to urea nitrogen creatinine can be remarkably increased, the fibrosis positive area can be remarkably reduced, and the bioavailability of the radix morindae officinalis-synanthrin composition is improved. The traditional Chinese medicine composition has a remarkable effect on treating renal fibrosis diseases. The raw materials of the composition are based on natural polysaccharides, so that the composition has good safety and degradability, and meets the high requirement of the medical field on the safety of biological materials. Compared with an existing single component, the compound design can achieve the multi-target effect, the treatment effect is remarkably improved, and the compound medicine has the large market competitive advantage.

The invention provides a creatinine sensor based on an asymmetric Mach-Zehnder structure, and belongs to the technical field of biological optical sensing. The sensor comprises a PDMS lower cladding, a PMMA core layer and a PDMS upper cladding, the PMMA core layer comprises an input waveguide, a beam splitter, a modulation arm waveguide, a beam combiner and an output waveguide, and the modulation arm waveguide comprises a sensing arm and a reference arm which are unequal in width. The sensing arm adopts a suspended design and is windowed, and a creatininase mixed solution is fixed on the surface of the sensing arm so as to increase the response to the creatinine concentration. Through optimal design of the width of the reference arm, the sensitivity of the reference arm is reduced, and the phase change of an interference signal is mainly caused by the sensing arm, so that the sensing sensitivity is improved. The sensor can detect the creatinine concentration within the range of 0-110 [mu] moL / L, covers the physiological concentration range of creatinine in human blood, has the characteristics of high sensitivity and compact structure, and is suitable for wearable health detection application.

The invention belongs to the technical field of biological medicines, and particularly relates to application of poecilobdella manillensis in preparation of a medicine for treating renal injury. The invention provides a new application of poecilobdella manillensis in preparation of a medicine for treating renal injury, serum biochemical index detection proves that the poecilobdella manillensis can effectively reduce serum creatinine and blood urea nitrogen levels, increase serum albumin and total protein content, remarkably improve glomerular filtration function and protein metabolism function, and improve renal function. And the improvement degree of the traditional Chinese medicine composition is superior to that of a traditional Chinese medicine contrast. Although the curative effect is slightly poorer than that of a chemical drug group, the safety advantage is remarkable. The poecilobdella manillensis can comprehensively regulate renal function metabolism indexes, relieve kidney injury and avoid common side effects of chemical drugs, provides a new choice for clinical treatment of kidney injury, and is especially suitable for chronic kidney disease patients needing long-term treatment.

The invention provides a clinical rehabilitation data management and evaluation system for a rhabdomyolysis patient, and relates to a medical information management system. The system comprises an index acquisition module, a rate detection module, a curvature analysis module, a node identification module and a trend construction module. According to the method, the rate difference sequence of creatine kinase and myohemoglobin and the curvature sequence of urine sodium and serum creatinine are compositely calculated, the limitation of traditional single-parameter static analysis is broken through, the dynamic capture of a multi-index collaborative trend is realized, and a joint evolution label system is constructed by combining the consistency judgment of creatine kinase and blood potassium concentration change directions; according to the method, multi-system interaction risk nodes are accurately positioned, statistics is performed on direction consistency proportional distribution of myoglobin and serum creatinine in an association time period, discrete parameter association is converted into a dynamic visual model, and the problems of data discreteness misjudgment and collaborative evolution mode splitting in the traditional technology are solved. And a multi-dimensional dynamic evaluation framework of the rhabdomyolysis rehabilitation process is provided for clinic.

The invention discloses a construction method of a rivaroxaban population pharmacokinetic model and application of the rivaroxaban population pharmacokinetic model in an individualized medication prediction model, and relates to the field of biological information. According to the invention, a high performance liquid chromatography-tandem mass spectrometry method is adopted to determine the blood concentration of a rivaroxaban taking person, and a DNA sequencing method is adopted to determine the gene polymorphism of related metabolic enzymes CYP3A4 and CYP3A5 and transporters ABCB1 and ABCG2 of the rivaroxaban taking person; collecting data to establish a rivaroxaban group pharmacokinetic model, performing internal verification, and evaluating the stability and prediction performance of the model; in the final PPK model, the influence of the creatinine clearance rate, the ABCB1rs1045642 and the health condition on the clearance rate is the greatest; the experimental verification result shows that the model has good predictability and is accurate and reliable; the method can be applied to an individualized medication prediction model.

The invention provides novel application and a method of asiaticoside. The method comprises the following steps: S1, extraction: taking a centella asiatica medicinal material, performing coarse crushing, adding ethanol, performing reflux extraction, performing filtration, and combining filtrate for standby application; s2, concentrating: concentrating the ethanol extracting solution under reduced pressure until no alcohol smell exists, centrifuging, and reserving supernate for later use; s3, carrying out D101 column chromatography; s4, alumina column chromatography; s5, performing concentration; s6, drying; s7, dissolving with methanol, adding water, standing, and monitoring clear liquid and crystallization conditions in a liquid phase; s8, filtering after crystallization is finished, washing with ethanol, drying crystals under the conditions that the vacuum degree is-0.06 to-0.08 mpa and the temperature is 60-70 DEG C, and crushing and sieving dry paste to obtain asiaticoside; specifically, the new application comprises reduction of uric acid (UA), urea (UREA), creatinine (CREZ), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and total cholesterol (CHOL) in serum of a hyperuricemia model SD rat, and reduction of damage of hyperuricemia to kidney. And the yield of asiaticoside extracted by the method is high and is about 84%.

The invention belongs to the technical field of nano-enzymes, and particularly relates to a preparation method and application of a porous RuO2 nano-enzyme for detecting creatinine. Comprising the following steps: ultrasonically dispersing Ca (NO3) 2.4 H2O, RuCl3 and glycine in deionized water to obtain a mixed solution A; dissolving sodium alginate in deionized water, and uniformly stirring to obtain a mixed solution B; injecting the mixed solution B into the mixed solution A, slowly stirring to form bimetallic hydrogel, washing with deionized water, and freeze-drying to obtain a solid A; calcining the solid A to obtain a solid B; and adding the solid B into hydrochloric acid for ultrasonic dispersion, stirring for a period of time, and centrifugally washing and drying the precipitate in vacuum to obtain the loose and porous RuO2 nano-particles. The nanoparticles prepared by the invention have abundant pore structures and great specific surface area, active sites can be fully exposed, and the POD enzyme activity is remarkably improved.

The invention belongs to the technical field of biological medicines, and particularly discloses a novel application of Epiblastatin A in preparation of a medicine for relieving cisplatin-induced acute kidney injury. The application disclosed by the invention for the first time reveals that by inhibiting the activity of Casein Kinase 1 (CK1) kinase, Epiblastine A can obviously relieve renal dysfunction and kidney tissue structure damage caused by cis-platinum. Experiments prove that the compound can effectively reduce serum creatinine and urea nitrogen levels, significantly improve renal tubule pathological injury, down-regulate expression of renal injury early-stage specific biomarkers KIM-1 and NGAL, and definitely inhibit renal tubule epithelial cell apoptosis in an in-vitro model. The invention also provides a specific pharmaceutical composition containing the Epiblastin A and a preparation form of the specific pharmaceutical composition. The invention provides a brand new mechanism and a high-efficiency and low-toxicity treatment strategy for clinically preventing and treating cisplatin dosage-limited renal toxicity, and has important clinical application value.

The present invention relates to a uric acid-lowering probiotic complex and its application. The probiotic complex comprises Lactobacillus reuteri FPH2951 and Bifidobacterium breve FPHC4024; wherein Lactobacillus reuteri FPH2951 is classified as Lactobacillus reuteri and has a deposit number of GDMCC No. 62946; and Bifidobacterium breve FPHC4024 is classified as Bifidobacterium breve and has a deposit number of GDMCC No. 62945. The probiotic complex of the present invention can significantly reduce serum uric acid (UA), creatinine (Cr), and blood urea nitrogen (BUN) levels and increase urine excretion of creatinine (Cr) and blood urea nitrogen (BUN) through the synergistic effect of Lactobacillus reuteri FPH2951 and Bifidobacterium breve FPHC4024, and has broad application prospects.

The invention discloses Fe3O4-V2O5 ultramicro composite foam nano-enzyme for serum creatinine detection as well as a preparation method and application of the Fe3O4-V2O5 ultramicro composite foam nano-enzyme, and belongs to the technical field of serum creatinine detection and nano-enzyme preparation. Comprising the following steps: (1) dissolving vanadium dichloride, ferric trichloride hexahydrate and cane sugar in an ethanol solution, then adding a phytic acid aqueous solution, and drying to obtain a first solid; and (2) placing the first solid in a Joule thermal device graphite sample table, and carrying out rapid Joule thermal shock in an air atmosphere to obtain the Fe3O4-V2O5 ultramicro composite foam nano-enzyme. The sucrose is used as a template agent, so that the formation of an ultramicro composite foam structure is promoted, the specific surface area of the material is remarkably increased, and more active sites are provided. The synergistic effect between Fe3O4 and V2O5 improves the catalytic activity of the active site. The porous structure effectively prevents agglomeration of nano-enzyme, and provides more channels for rapid recognition and reaction of serum creatinine.

The invention relates to a traditional Chinese medicine composition for treating diabetic nephropathy and a preparation method thereof, and belongs to the technical field of traditional Chinese medicine compositions. In order to solve the problems that the target spot of western medicine for treating diabetic nephropathy is single, and the adverse reaction risk is large when multiple medicines are combined for use, the invention provides a traditional Chinese medicine composition for treating diabetic nephropathy, and the traditional Chinese medicine composition comprises white ginseng, astragalus membranaceus, scorched atractylodes macrocephala, poria cocos, endothelium corneum gigeriae galli, kudzu vine root, medlar, Chinese yam, dogwood and rhizoma alismatis. The traditional Chinese medicine composition has the advantages of multiple components, multiple targets and small adverse reaction, animal experiments prove that the traditional Chinese medicine composition provided by the invention can remarkably improve the levels of blood sugar, blood fat, urine protein, creatinine and urea nitrogen of rats, can remarkably improve pathological changes of renal tissues of model rats, can specifically increase the activity of SIRT1 and PGC-1alpha, and can be used for treating the renal diseases of the rats. The traditional Chinese medicine composition can be used for treating diabetic nephropathy, correcting the metabolic pathway of podocyte and recovering the mitochondrial function, is an effective medicament for treating diabetic nephropathy, and provides a new pathway for clinical multi-target treatment of diabetic nephropathy.

The invention relates to application of bacillus coagulans BC99 in preparation of a probiotic preparation for assisting in reducing the uric acid level. The bacillus coagulans BC99 is a bacillus coagulans BC99 strain of which the preservation number is CGMCC (China General Microbiological Culture Collection Center) No. 21801, and the bacillus coagulans BC99 strain of which the preservation number is CGMCC No. 21801. The invention finds that the bacillus coagulans BC99 has a very remarkable effect in the aspect of assisting in reducing uric acid, and the effect is specifically shown as follows: the levels of serum uric acid, urea nitrogen and creatinine of a hyperuricemia rat are reduced; the xanthine oxidase activity of the hyperuricemia rats is improved; the serum inflammatory factor level of the hyperuricemia rats is regulated, and the inflammatory reaction caused by uric acid increase is inhibited; and the levels of glutamic oxalacetic transaminase and glutamic-pyruvic transaminase of high-uric-acid rats Meanwhile, the bacillus coagulans BC99 is used as a probiotic, so that the product is high in safety and not easy to generate resistance.

The invention provides a soybean peptide with an effect of preventing and / or treating chronic nephritis as well as a preparation method and application of the soybean peptide, and belongs to the technical field of bioactive peptides. According to the preparation method of the soybean peptide mixture provided by the invention, a three-step enzymolysis mode is adopted, the molecular weight of soybean peptide is controlled to be 1000 Daltons or below, micromolecular oligopeptide is used as a main component, and the prepared soybean peptide mixture is low in sodium, phosphorus and potassium content and capable of improving the nutritional status and muscle loss condition of nephritis patients. The prepared soybean peptide mixture is further separated and purified, the purified soybean peptide mixture, the single-chain polypeptide S1 and the single-chain polypeptide S2 are obtained, the content of uric acid and creatinine can be effectively reduced, inflammation can be inhibited, and the soybean peptide is expected to be developed into a novel polypeptide medicine for preventing and / or treating chronic kidney diseases.

The invention discloses application of colla corii asini bone-strengthening oral liquid to prevention and / or treatment of anemia, and belongs to the technical field of medicines, and the anemia comprises iron-deficiency anemia, renal anemia and myelosuppression anemia. The colla corii asini bone strengthening oral liquid can increase erythrocyte count, hemoglobin concentration, hematocrit, erythrocyte average hemoglobin amount, erythrocyte average hemoglobin concentration and / or erythrocyte average volume; the serum iron content is increased; a transporter divalent metal transporter and a membrane iron transporter are increased; the intestinal iron absorption is promoted. The composition specifically comprises urea nitrogen and creatinine; related indexes of renal anemia are improved; the immune index of renal anemia can be improved. The percentage of leukocytes and lymphocytes of anemia caused by myelosuppression can be recovered; the hemoglobin content is increased; the number of macrophage colony stimulating factors and / or bone marrow cells in serum is increased; the immunocompetence is improved; the proliferation of lymphoid B cells and macrophages is promoted.

The invention discloses a creatinine detection device, and belongs to the field of in-vitro diagnosis equipment. The creatinine detection device comprises a substrate, a reagent 1 assembly and a reagent 2 assembly, the reagent 1 assembly comprises a flow pad, an enzyme pad and a blood filter membrane, the reagent 2 assembly comprises a start inhibition layer, a separation layer and a color development layer, the reagent 1 assembly and the reagent 2 assembly are stored in a non-contact mode in a normal state, and the reagent 1 assembly and the reagent 2 assembly are in contact to start a reaction during testing; the separation layer contains perfluorooctane sulfonic acid and / or perfluorooctane carboxylic acid. According to the creatinine detection device provided by the invention, interference of endogenous ammonia can be eliminated, the diffusivity of the ammonia is improved, and the detection sensitivity is improved.

The invention belongs to the technical field of medicines, and particularly discloses a biomarker for detecting kidney fibrosis related diseases and application of the biomarker. The biomarker comprises serum copper cyanin, or the serum copper cyanin and serum creatinine. Compared with other methods for diagnosing renal fibrosis, the serum cupreuloplasmin has the following three advantages: 1, compared with a conventional diagnostic marker (such as serum creatinine), the cupreuloplasmin can detect up-regulation in the serum of a patient suffering from early chronic kidney diseases, and can be combined with an existing mature diagnostic marker for detection; secondly, compared with renal tissue pathologic biopsy, the use of the copper cyanin as the diagnostic marker has non-invasiveness, and only a small amount or even a trace amount of patient serum is needed, so that the harm to the body health of the patient is avoided; and thirdly, compared with a nuclear magnetic resonance method for analyzing the metabolic components of the urine, the method for detecting the markers in the serum is lower in cost, more flexible, high in timeliness and easier to popularize.